Healthy Volunteers Enteral Nutrition Study (HEN)
HEN
1 other identifier
interventional
25
0 countries
N/A
Brief Summary
This research study is being conducted to determine the effects of enteral nutrition on healthy people. Enteral nutrition for the purpose of this study refers to the use of a specially developed formula taken by mouth that provides all essential nutrition either in the absence of food or to supplement the intake of foods. Enteral nutrition can be used for many reasons, such as to gain or lose weight, to treat food allergies, or to reduce inflammation in certain intestinal diseases. We would like to understand the effects of enteral nutrition in the absence of intestinal inflammation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 16, 2026
CompletedFirst Posted
Study publicly available on registry
February 23, 2026
CompletedStudy Start
First participant enrolled
April 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2027
February 24, 2026
February 1, 2026
1 year
February 16, 2026
February 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
number of sitz markers at 72 hours
Number of sitz markers that are present in an abdominal x-ray 72 hours after the participant takes the sitz mark capsule
72 hours after taking the sitzmark capsule
Study Arms (2)
Partial Enteral Nutrition and the Crohn's Disease Exclusion Diet
ACTIVE COMPARATORParticipants will drink Kate Farms Peptide 1.5 for 60% of their calories and follow the Crohn's Disease Exclusion Diet for the remainder of their calories
Exclusive enteral nutrition
ACTIVE COMPARATORParticipants will consume Kate Farms Peptide 1.5 exclusively except water, and coffee and tea with no sweetner or cream/milk for 3 days
Interventions
Kate Farms Peptide 1.5
This study will use the components of the Crohn's disease exclusion diet Phase 1 which includes chicken breast, eggs, potatoes, bananas and apples
Eligibility Criteria
You may qualify if:
- Must be able to read and understand English
- Must be able to sign a consent form for the study
You may not qualify if:
- BMI \<20 or \>30
- Unintentional weight loss of \>10% in the last 3-6 months
- Kidney disease
- Diagnosis of cirrhosis
- Taking diuretics
- Anemia - Hemoglobin \<lower limit of normal in men or \<10 g/dL in women.
- Taking iron supplements within 2 weeks for Visit 2.1
- Taking prebiotic or probiotic supplements or any supplement including a multivitamin within 2 weeks of Visit 2.1
- Taking antibiotics less than 4 weeks prior to Visit 2.1
- Diarrhea in the 2 weeks prior to Visit 2.1
- Diabetes mellitus
- Diagnosis of congestive heart failure
- Diagnosis of inflammatory bowel disease or celiac disease
- Bowel resection other than an appendectomy
- Pregnancy or breastfeeding
- +6 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- James Lewislead
Study Officials
- PRINCIPAL INVESTIGATOR
James Lewis, MD, MSCE
University of Pennsylvania
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor of Medicine and Epidemiology
Study Record Dates
First Submitted
February 16, 2026
First Posted
February 23, 2026
Study Start
April 1, 2026
Primary Completion (Estimated)
April 1, 2027
Study Completion (Estimated)
May 1, 2027
Last Updated
February 24, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share
Due to the small sample size, there is risk of participant identification. However, we will consider requests to access deidentified data on an individual basis and under a data use agreement.